[Actual Letter Hidden behind Pay Wall]
Correspondence to Dr Elizabeth L Durmowicz, Office of Science, Center for Tobacco Products, Food and Drug Administration, WO 75/Room 5476, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA; Elizabeth.durmowicz@fda.hhs.gov
Received 15 January 2015
Accepted 3 April 2015
Published Online First 23 April 2015
The US Food and Drug Administration (FDA) Center for Tobacco Products (CTP) receives and reviews voluntary reports from consumers, healthcare professionals and members of the public on adverse experiences (AEs) associated with tobacco products. Reports from consumers and concerned citizens have described AEs not only in users, but also in non-users of e-cigarettes.1 ,2
AE reports received by FDA between 1 January 2012 and 31 December 2014 were reviewed to evaluate AEs associated with e-cigarettes in non-users. The reports were received via the Safety Reporting Portal, MedWatch, mail and email. Of 136 reports related to e-cigarette AEs, 40 involved non-users (table 1).
Thirty-five reports were related to passive aerosol exposure (typically in indoor spaces). Respiratory symptoms …
